International Business News - ALXN http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Alexion Pharmaceuticals Inc. said Tuesday David Keiser will retire as president and chief operating officer at the end of the year. The company said Keiser's responsibilities would be distributed among Alexion's management team, reporting to Chief Executive Leonard Bell. http://www.ibtimes.com/articles/20081111/alexion-president-coo-keiser-to-retire.htm Tue, 11 Nov 2008 10:55:09 EST Among the earnings stories for Thursday, Oct. 23, from AP Financial News: Top stories: http://www.ibtimes.com/articles/20081023/earnings-roundup-chrysler-alexion.htm Thu, 23 Oct 2008 14:33:54 EDT Alexion Pharmaceuticals Inc. said Thursday it swung to a third-quarter profit on a surge in sales of its rare blood disorder drug Soliris. Soliris treats paroxysmal nocturnal hemoglobinuria, a condition that involves a breakdown of red blood cells and can lead to anemia. It is Alexion's only approved drug. http://www.ibtimes.com/articles/20081023/alexion-swings-to-3q-profit-on-soliris-sales.htm Thu, 23 Oct 2008 18:18:27 EDT Drug developer Alexion Pharmaceuticals Inc. said Tuesday its board of directors approved a 2-for-1 stock split. The stock split, which will double the number of shares outstanding, will be effected in the form of a stock dividend. The split is effective Aug. 22 to shareholders of record as of Aug. 12. http://www.ibtimes.com/articles/20080729/alexion-pharmaceuticals-board-sets-stock-split.htm Tue, 29 Jul 2008 12:19:27 EDT Drug developer Alexion Pharmaceuticals Inc. said Tuesday it expects to report a profit for the next two quarters, and boosted sales guidance for its only product, Soliris. http://www.ibtimes.com/articles/20080729/alexion-raises-2008-revenue-outlook.htm Tue, 29 Jul 2008 12:16:25 EDT A surge in sales of Alexion Pharmaceuticals' rare blood disorder drug Soliris pushed the drug developer to a second-quarter profit, and boosted shares to their highest level in about eight years Tuesday. http://www.ibtimes.com/articles/20080729/alexion-shares-hit-new-high-on-2q-profit-outlook.htm Tue, 29 Jul 2008 12:11:33 EDT Wider international expansion, the confluence of pharmacies and drug suppliers, and a more aggressive generic drug industry will be in focus at the Goldman Sachs annual health care conference in California next week. http://www.ibtimes.com/articles/20080606/goldman-opens-annual-health-care-conference-monday.htm Fri, 06 Jun 2008 15:19:39 EDT Among the premarket stories for Thursday, May 29, from AP Financial News: NEW YORK (AP)--A Stifel Nicolaus & Co. analyst upgraded SunTrust Banks Inc. on Thursday, in part because of a recent drop in shares, and said further drops should be limited. http://www.ibtimes.com/articles/20080529/premarket-roundup-suntrust-banks-orbitz.htm Thu, 29 May 2008 09:25:37 EDT A Piper Jaffray analyst set a "Buy" rating on Alexion Pharmaceuticals Inc. Thursday, saying the company's drug Soliris could become a billion-dolar "blockbuster." http://www.ibtimes.com/articles/20080529/ahead-of-the-bell-alexion-pharma.htm Thu, 29 May 2008 08:35:25 EDT The president and chief operating officer of biotechnology company Alexion Pharmaceuticals Inc. exercised options for 50,000 shares of common stock, according to a filing with the Securities and Exchange Commission. http://www.ibtimes.com/articles/20080506/alexion-pharmaceuticals-president-exercises-options.htm Tue, 06 May 2008 15:37:44 EDT